Transient ischaemic attack after spacing the dose of alirocumab: Is it advisable to reduce the doses of PCSK9 inhibitors with very low LDL-cholesterols?

  1. Piqueras Ruiz, S.
  2. Parra Virto, A.
  3. Torres do Rego, A.
  4. Demelo Rodríguez, P.
  5. Álvarez-Sala Walther, L.
Journal:
Clinica e Investigacion en Arteriosclerosis

ISSN: 1578-1879,  0214-9168

Year of publication: 2020

Volume: 32

Issue: 1

Pages: 30-32

Type: Article

DOI: 10.1016/J.ARTERI.2019.04.003 GOOGLE SCHOLAR
Data source: Scopus